Navigation Links
Stallergenes: Launch of a Phase III Clinical Trial in Adults for Oralair(R) Grasses in the United States Operating Income Expected to Remain Stable in 2009
Date:10/27/2008

ANTONY, France, October 27 /PRNewswire-FirstCall/ -- Stallergenes has just obtained authorization (IND(1)) from the FDA for immediately launching a phase III clinical trial in the United States with Oralair(R) Grasses in the treatment of allergic rhinoconjunctivitis to grass pollens in adults.

The aim of the study, which will be conducted in 450 American patients during the 2009 pollen season, is to confirm the efficacy and good tolerance of the product in adults and to support the application for authorization to market it in the United States.

"This IND application for a phase III study is testimony to our company's capacity to meet the FDA's requirements," states Albert Saporta, President & CEO of Stallergenes. "In order to reinforce our attractiveness as we look forward to the prospect of a US partnership for marketing Oralair(R), we are naturally conducting this development with Quintiles, our longstanding partner for all the post-phase I development of the Oralair program, i.e. seven phase IIb/III or III studies (studies already conducted and those still underway). There is no doubt that this combined cumulative experience gives us real expertise, which is crucial when it comes to setting up studies and interfacing with agencies, particularly the FDA."

"2009 will be an exceptional year, with the results of four major phase IIb/III or III clinical studies: the Oralair(R) Mites pivotal study, the Oralair(R) Birch pollen (rBet v 1) study, the Oralair(R) Grasses long term efficacy and this one about Oralair(R) grasses in the United States."

"All of these elements will enable us, when the time comes, to optimize the terms of a strategic partnership. The planned R&D investment levels are compatible with the operating income in value in 2009 remaining at its 2008 level."

About Oralair(R) Grasses

Oralair(R) Grasses is a fast-dissolving sublingual desensitization tablet indicated in the treatment of allergic rhinoconjunc
'/>"/>

SOURCE Stallergenes
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Stallergenes: Sales at end September 2008: + 17% - 2008 Sales Guidance Revised Upwards: + 14%
2. Stallergenes: First Half Year 2008: A 19% Increase in Operating Profit and Net Profit
3. Stallergenes: Q2 2008 Sales up 18% Revision Upwards of 2008 Sales Growth
4. STALLERGENES: 2007: A Further Year of Strong Growth: Up 16%
5. STALLERGENES: ORALAIR Grasses: Positive Results of VO52.06 Paediatric Study
6. Rosetta Genomics Leverages its MicroRNA Platform Technologies to Launch Plant Biotech Initiative
7. Lilly Announces Launch of Color Differentiation System for Humalog(R) and Humulin(R) U-100 Insulin Products in the United States
8. The MaxCyte STX Scalable Transfection System to be Launched at the SBS Symposium on Cell-Based Assays
9. HealthYes! - Premier Provider of Mobile Preventive Medical Screenings - Launches in Alamo City
10. Sensorin Raises Equity Financing to Launch Novel Industrial Sensing Venture
11. Video: OneTouch(R) Teams With Online Diabetes Community to Launch Global Diabetes Handprint Project

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)..., Nov. 19 Omeros Corpora...nancial results for the third quarter ended Septem... 30, 2009, Omeros reported a net loss of $3.9 mill... of $7.4 million, or $2.54 per share, for the same...er 30, 2009, the Company reported a net loss of $1...
(Date:11/19/2009)..., BETHESDA, Md., Nov. 19 /PRNewswire-FirstCall/...vator in biotechnology for diabetes therapy, and a...ervices to food, supplement, biotechnology and pha...he previously reported $6.3 million registered dir...870 shares of its common stock and warrants to pur...
(Date:11/19/2009)...A, Md., Nov. 19 Spherix ...technology for diabetes therapy, and a provider of...ood, supplement, biotechnology and pharmaceutical ...s Annual Meeting of Shareholders. ,, At the mee...: SPEX ) elected the following members to the Boa...
(Date:11/19/2009)...MUNSTER, Germany, November 19 MONI...n November 16th, 2009 Flibanserin in the,indicatio...n Parkinson,s,disease for orphan drug status desig...Levodopa-induced dyskinesia is a complication of t...a serious burden to some of those,affected, since ...
Breaking Biology Technology:Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8Spherix Announces the Closing of $6.3 Million Registered Direct Offering 2Spherix Announces the Closing of $6.3 Million Registered Direct Offering 3Spherix Announces Results of Annual Shareholders Meeting 2Spherix Announces Results of Annual Shareholders Meeting 3Spherix Announces Results of Annual Shareholders Meeting 4MONITORING FORCE GmbH Requests Acknowledgment of Flibanserin as "Orphan Drug" 2
...OLLEGE PARK, Md. -- University of Maryland physic...it to the mobility, a measure of how well a materi...known material at room temperature. Graphene, a si...al which combines aspects of semiconductors and me...urnal Nature Nanotechnology, indicate that graphen...
...INGTON, March 24 America,s,pharmaceutical and bio...8.8,billion last year in the research and developm... an increase of nearly $3 billion from 2006,accord... Manufacturers of,America (PhRMA) and Burrill & Co...RMA,s 50th anniversary, which it observes today., ...
...NA, Va., March 24 CMPMedica has expanded,SearchMe...l search,applications for specialist medical condi...vera Corporation (Nasdaq: CNVR ), http://www.con...services for publishers., (Logo: http://www.news...chMedica.com has been serving primary health care ...
Other Biology Technology:UM physicists show electrons can travel over 100 times faster in graphene than in silicon 2UM physicists show electrons can travel over 100 times faster in graphene than in silicon 3R&D Spending by U.S. Biopharmaceutical Companies Reaches Record $58.8 Billion in 2007 2R&D Spending by U.S. Biopharmaceutical Companies Reaches Record $58.8 Billion in 2007 3CMPMedica Expands SearchMedica.com with Multiple Additional Vertical Search Applications co-developed with Convera(R) 2CMPMedica Expands SearchMedica.com with Multiple Additional Vertical Search Applications co-developed with Convera(R) 3
(Date:11/22/2009)... , A team of pioneering South Korean scientists h...veryday plastics through bioengineering, rather th... This groundbreaking research, which may now allow...lastics, is published in two papers in the journal...urnal,s 50th anniversary. , Polymers are molecu...
(Date:11/22/2009)... , Scientists at the Brain Research Centre, a par...ulty of Medicine and Vancouver Coastal Health Rese...ut the mechanism by which brain cells die followin...that damage. The results of the study were recentl...wing a stroke, many brain cells continue to die ev...
(Date:11/20/2009)... , Using highly precise measurements of plasma li...netic resonance spectroscopy (NMR), researchers le...l and Harvard Medical School in Boston, MA, the Fr...DIS consortium in Stockholm, Sweden and Oxford, En...s the whole genome among 17,296 women of European ...
Breaking Biology News(10 mins):Bioengineers succeed in producing plastic without the use of fossil fuels 2New understanding about mechanism for cell death after stroke leads to possible therapy 2Genetic analysis helps dissect molecular basis of cardiovascular disease 2Cardinal George Lauds House Action to Ban Federal Funds for Abortion 3B Promises Vigilance as Senate Pursues Health Care Reform Wary About Affect on 61022 1Cardinal George Lauds House Action to Ban Federal Funds for Abortion 3B Promises Vigilance as Senate Pursues Health Care Reform Wary About Affect on 61022 2Cardinal George Lauds House Action to Ban Federal Funds for Abortion 3B Promises Vigilance as Senate Pursues Health Care Reform Wary About Affect on 61022 3Surgical Care Affiliates Announces Investor Conference Call to Discuss 2009 Third Quarter Results 6114 1Hill Rom and Encompass Group Form Joint Venture 6110 1Hill Rom and Encompass Group Form Joint Venture 6110 2Hill Rom and Encompass Group Form Joint Venture 6110 3Hill Rom and Encompass Group Form Joint Venture 6110 4Hill Rom and Encompass Group Form Joint Venture 6110 5
...C. By coupling a kicked-up version of microscopy ...scientists are now able to peer so deep into livin..., If future studies in animal models prove fruitf...h can have a wide spectrum of clinical application...emoved from the body to assessing the effects of a...
... 17, 2008, Cambridge, UK , Knee scrapes and tumo... , The idea that tumor growth triggers the same ...y controversial notion. However, increasing evide...nisms which heal a skinned knee might also have a ... published today in Disease Models & Mechanisms ...
...ptember 16, 2008 The City College of New York (CC...n over five years from the National Science Founda...esearch center that will investigate new applicati...s and energy systems. Known as CENSES (Center for ...gy Systems), the center will also investigate emer...
Other Biology News:New technique sees into tissue at greater depth, resolution 2New technique sees into tissue at greater depth, resolution 3CCNY receives $5 million NSF grant to establish center for nanostructure applications 2
Hoagland's No. 2 Basal Salt Mixture from Sigma-Aldrich
...s and MDS Sciex present the 4000 Q TRAP(TM) LC/MS/...pole/linear ion trap mass spectrometer for the dru...cher. Innovative Linear Ion Trap (LIT) Technology ...her fast, sensitive qualitative analysis with the ...
... is an isotonic, balanced salt solution. It is rou..., which permits the storage of whole blood at refr... For usage, an equal volume of blood is collected ...horoughly, mixed. The solution is placed in a refr...
Rabbit Anti-GST Polyclonal Antibody, Unconjugated from Novus Biologicals
Biology Products: